BioNTech SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ugur Sahin
- Full Time Employees
- 7,807
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- An der Goldgrube 12 Mainz RP Germany 55131
- IPO Date
- Oct 10, 2019
- CIK
- 0001776985
- Website
- biontech.com
- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
Company News
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 46,000 Shares of Stock
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 33,000 Shares
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX)
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Ugur Sahin Sells 41,000 Shares of BioNTech (NASDAQ:BNTX) Stock
Ugur Sahin Sells 45,000 Shares of BioNTech (NASDAQ:BNTX) Stock
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Is BioNTech Stock a No-Brainer Buy on the Dip?
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC's ‘Final Trades'
BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
BioNTech Kills a Cancer Trial Roche Helped Build
BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat